American journal of cancer research最新文献

{"title":"Imaging-guided SMART improves survival in locally advanced and borderline resectable pancreatic cancer: a comparative study.","authors":"Nianhui Jiao, Huiqin Qi, Xuejun Li, Yongjie Qi, Yanjie Sun","doi":"10.62347/XKSS2851","DOIUrl":"10.62347/XKSS2851","url":null,"abstract":"<p><p>Pancreatic cancer remains notoriously challenging to treat due to its aggressive nature and complex anatomic location. Late-stage diagnoses often result in high mortality rates. This study assesses the effectiveness of combining ablative stereotactic MRI-guided intensity-modulated radiation therapy (SMART) with chemotherapy for treating locally advanced and borderline resectable pancreatic cancer. We retrospectively analyzed 235 pancreatic cancer patients treated between 2020 and 2023. Patients were divided into chemoradiation (SMART + chemotherapy, n = 106) and chemotherapy-only (n = 129) groups. Key outcomes included progression-free survival, overall survival, margin-negative resection rates, lymphovascular invasion, and toxicities. The chemoradiation group demonstrated improved PFS (8.30 ± 1.20 vs. 7.90 ± 1.30 months, P = 0.015) and OS (14.30 ± 2.60 vs. 13.50 ± 2.40 months, P = 0.015), with higher rates of margin-negative resections (92.45% vs. 80.62%, P = 0.009) and reduced LVI (37.74% vs. 52.71%, P = 0.022) compared to chemotherapy alone. However, acute toxicities, including fatigue and abdominal pain, were more frequent in the chemoradiation group. Locoregional control and distant metastasis-free survival showed no significant group differences (P > 0.05). Overall, SMART enhances local tumor control and survival outcomes in severe pancreatic cancer, albeit with increased acute toxicity.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2604-2617"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraosseous versus intravenous fluid resuscitation in gastrointestinal tumor-related acute hemorrhage: impact on 30-day mortality and lactate clearance.","authors":"Juan Chen, Chunmei Zhang, Xiaowei He, Xiaoqin Han, Yingzhe Su, Chunyan Chen, Wenxia Xu, Wei Yang","doi":"10.62347/EAMR9595","DOIUrl":"10.62347/EAMR9595","url":null,"abstract":"<p><p>This retrospective study evaluated the impact of intraosseous infusion (IO) versus traditional intravenous infusion (IV) on 30-day mortality and clinical outcomes in 518 patients with acute gastrointestinal bleeding (AGIB) secondary to gastrointestinal tumors from January 2022 to July 2024. Patients were divided into IO (n=217) and IV (n=301) groups based on initial resuscitation strategy. Compared to IV group, the IO group demonstrated higher first-attempt catheterization success rate, shorter vascular access time, and faster blood pressure recovery (all P<0.001), alongside higher 6-hour lactate (LA) clearance (34% vs. 22%, P<0.001) and lower 30-day mortality (11.98% vs. 18.6%, P=0.016). Multivariate analysis identified IO infusion as protective factor for lactate metabolism (HR=0.289, 95% CI: 0.092-0.864), while advanced age (HR=1.125), diabetes (HR=3.23), and low LA clearance (HR=0.016) were independent risk factor for mortality. Causal mediation analysis revealed that 6-hour LA clearance mediated 68% of the IO-associated mortality reduction (P<0.001), whereas diabetes history was not a significant mediator (P=0.156). Complication rates were comparable between groups (P>0.05). These findings indicate that IO infusion improves survival in AGIB due to gastrointestinal tumors by rapidly restoring hemodynamics and enhancing lactate metabolism. The mortality benefit is primarily driven by accelerated LA clearance rather than comorbidities like diabetes. Given its safety profile comparable to IV, IO infusion should be prioritized in critical care settings.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2682-2700"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PINX1 inhibits proliferation and cisplatin resistance in nasopharyngeal carcinoma by promoting ILF3 ubiquitination.","authors":"Ni Zhou, Pinggui Gong, Shuilian Wang, Cui He, Liya Hu, Hong Peng","doi":"10.62347/WFER2605","DOIUrl":"10.62347/WFER2605","url":null,"abstract":"<p><p>PIN2/TRF1-interacting telomerase inhibitor 1 (PINX1) acts as a tumor suppressor in various cancers, yet its molecular role in nasopharyngeal carcinoma (NPC) remains poorly defined. This study investigates the therapeutic potential of PINX1 in NPC. Expression levels of PINX1 and interleukin enhancer-binding factor 3 (ILF3) were assessed in NPC cells and tissues via western blotting and immunohistochemistry, and their correlation with patient prognosis was analyzed. The effects of ILF3 on NPC cell proliferation and cisplatin resistance were evaluated using cell cycle analysis, EdU incorporation, CCK-8, and IC₅₀ assays. Co-immunoprecipitation and immunofluorescence confirmed the interaction between PINX1 and ILF3, while qPCR and western blotting assessed their regulatory relationship. Bioinformatics analysis, chromatin immunoprecipitation, and dual-luciferase assays were performed to identify transcription factors regulating PINX1. Additional in vitro experiments explored the antagonistic relationship between PINX1 and ILF3. Results showed that PINX1 expression was downregulated in NPC and associated with favorable prognosis, whereas ILF3 was upregulated and linked to poor outcomes. PINX1 physically interacted with ILF3 and promoted its ubiquitination through Speckle-type BTB/POZ protein (SPOP). Furthermore, signal transducer and activator of transcription 3 suppressed PINX1 transcription, while PINX1 antagonized the oncogenic effects of ILF3. Mechanistically, PINX1 facilitated ILF3 degradation via SPOP, suppressed the PI3K-AKT-mTOR pathway, inhibited tumor proliferation, and enhanced cisplatin sensitivity in NPC cells. These findings highlight the tumor-suppressive role of PINX1 and underscore its potential as a therapeutic target in NPC.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2518-2534"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Astragalus polysaccharides inhibits nasopharyngeal carcinoma progression through the mediation of the Akt/mTOR pathway and the induction of oxidative stress.","authors":"Ruojin Chen, Junyong Chen, Xuan Chen, Shangli Chen, Haiying Jia, Zhi Tang","doi":"10.62347/QSZR3302","DOIUrl":"10.62347/QSZR3302","url":null,"abstract":"<p><p>To investigate whether astragalus polysaccharides (APS) can inhibit the progression of nasopharyngeal carcinoma (NPC) and its underlying mechanisms, we conducted both cell and animal experiments. In NPC tissues and cell lines, the level of SNHG12 was significantly elevated, and high levels of SNHG12 were associated with advanced TNM staging, as well as increased cell viability and invasiveness. We further explored the mechanism by which SNHG12 promotes NPC progression and found multiple binding sites between SNHG12 and miR-30a-3p (miR-30a). The expression of miR-30a was significantly decreased in NPC tissues and cell lines, showing a strong negative correlation with SNHG12 levels. Moreover, SNHG12 could counteract the anti-cancer effects of miR-30a, enhancing the viability and migratory ability of CNE-2 cells. Further studies revealed that miR-30a could target and inhibit AKT3 levels, while SNHG12 could antagonize miR-30a and restore AKT3 levels. Thus, SNHG12 can regulate the malignant biological characteristics of NPC by targeting the miR-30a/AKT3 axis. In animal experiments, we found that APS can downregulate SNHG12 and upregulate miR-30a in tumor tissues, effectively suppressing NPC progression. Additionally, APS demonstrated significant antioxidant effects. Therefore, APS can inhibit oxidative stress and suppress NPC progression by targeting the SNHG12/miR-30a/AKT3 signaling pathway.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2469-2481"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The correlation between ALDH2 rs671 polymorphism and clinical prognosis in alcoholic liver disease-related hepatocellular carcinoma after curative resection.","authors":"Chih-Jan Ko, Wen-Lung Wang, Hung-Yu Lin, Pei-Min Hsieh, Szu-Ying Chen, Steven Yu Lin, Kuang-Chun Hu, James Yu Lin, Li-Wei Chou, Yaw-Sen Chen, Yu-Wei Huang, Chen-Ti Wang, Wen-Chao Ho, Chih-Wen Lin","doi":"10.62347/EVBS5360","DOIUrl":"10.62347/EVBS5360","url":null,"abstract":"<p><p>Whether the aldehyde dehydrogenase 2 (ALDH2) rs671 polymorphism predicts clinical prognosis in alcoholic liver disease (ALD)-related hepatocellular carcinoma (HCC) after hepatectomy remains unclear. Hence, this study aims to investigate the association between ALDH2 rs671 polymorphism and HCC recurrence and mortality in patients with ALD-related HCC who underwent hepatectomy. We also explored the risk factors for HCC recurrence and mortality in this population of patients. This retrospective cohort study enrolled 238 ALD-related HCC patients underwent hepatectomy from 2011 to 2022 at the E-Da Hospital, I-Shou University. Data analyses were finalized on October, 2023. Alcoholism was defined as consuming over 20 g of ethanol each day for at least 5 years. Patients with HBsAg-positive or/and HCV-positive status were excluded. ALDH2 rs671 polymorphism was analyzed. The endpoint was HCC recurrence and overall mortality. Of the 238 patients enrolled, 196 (82.4%) were men, and the mean (SD) age was 62.3 (10.2) years. HCC recurrence occurred in 70 patients, and 64 patients died. ALDH2 rs671 polymorphism was significantly associated with HCC recurrence and mortality. The 10-year cumulative HCC recurrence and mortality rates were significantly higher in patients with the ALDH2 rs671 genotype GA/AA relative to those with the ALDH2 rs671 genotype GG. In the Cox proportional analyses, the ALDH2 rs671 genotypes GA/AA (hazard ratio [HR]: 2.66, 95% confidence interval [CI]: 1.59-4.43, <i>P</i> = 0.000) and AST ≥ 40 IU/L (HR: 1.93, 95% CI: 1.18-3.17, <i>P</i> = 0.009) were significantly associated with increased HCC recurrence. Furthermore, the ALDH2 rs671 genotype GA/AA (HR: 2.02, 95% CI: 1.17-3.49, <i>P</i> = 0.012) and age ≥ 65 years (HR: 1.67, 95% CI: 1.01-2.78, <i>P</i> = 0.048) were significantly associated with increased mortality. In conclusion, the ALDH2 rs671 genotype GA/AA is significantly associated with unfavorable clinical prognosis in ALD-related HCC after hepatectomy.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2631-2641"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a predictive model for recurrence in postoperative glottic laryngeal squamous cell carcinoma patients following adjuvant chemotherapy based on PNI, NLR, and PLR.","authors":"Baoxiao Wang, Jianming Fan, Yu Li, Yajing Wang","doi":"10.62347/CYNY8714","DOIUrl":"10.62347/CYNY8714","url":null,"abstract":"<p><strong>Objective: </strong>To identify key factors influencing postoperative recurrence in patients with glottic laryngeal squamous cell carcinoma (LSCC) and to develop a predictive model incorporating traditional clinicopathological features and novel inflammatory and immune indicators. This model aims to provide a theoretical foundation for individualized prediction of postoperative recurrence risk and support clinical decision-making.</p><p><strong>Methods: </strong>Clinical and laboratory data were collected from 614 patients with glottic laryngeal cancer who underwent surgery between April 2010 and December 2021. The study included inflammatory and immune-related indicators (such as NLR, PLR, PNI, IL-6, IL-8), alongside traditional clinical features like age, T stage, lymph node metastasis, and degree of differentiation. Univariate and multivariate logistic regression, as well as Cox regression analyses, were performed to identify factors associated with recurrence. A Nomogram model was constructed based on Cox regression results. The model's predictive performance was evaluated using ROC curves, the concordance index (C-index), and calibration curves, with validation conducted in both training and validation cohorts.</p><p><strong>Results: </strong>Multivariate analysis identified age, T stage, lymph node metastasis, degree of differentiation, IL-6, IL-8, PNI, and PLR as independent factors influencing postoperative recurrence in patients with glottic laryngeal cancer. The Nomogram model demonstrated excellent predictive performance in both the training and validation cohorts, with AUCs for 12-, 24-, and 36-month recurrence-free survival predictions of 0.887, 0.906, and 0.915 (training cohort) and 0.895, 0.906, and 0.907 (validation cohort), respectively. The model's concordance indices were 0.860 and 0.857 in the training and validation groups, respectively. Calibration curves revealed a high degree of agreement between predicted and actual outcomes.</p><p><strong>Conclusion: </strong>The Nomogram model developed in this study integrates multiple clinical and inflammatory-immune indicators, enabling accurate prediction of 12-, 24-, and 36-month recurrence-free survival rates in post-surgical patients with glottic laryngeal cancer. The model holds significant clinical value, with IL-6, IL-8, and PNI identified as crucial indicators for predicting recurrence risk, providing valuable insights for postoperative follow-up and individualized treatment strategies.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2500-2517"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of cisplatin, paclitaxel combined with high-dose methotrexate as adjuvant therapy on survival rates in osteosarcoma patients, and analysis of influencing factors.","authors":"Yixin Wang, Lang Jin, Chuanjie Zong, Xidong Zhang","doi":"10.62347/RLWT8295","DOIUrl":"10.62347/RLWT8295","url":null,"abstract":"<p><p>Osteosarcoma is a prevalent primary malignant bone tumor in young adults and adolescents, characterized by a high recurrence rate despite advancements in chemotherapy and surgical methods. This study investigated the effects of integrating high-dose methotrexate with cisplatin and paclitaxel on survival outcomes in osteosarcoma patients, and to identify prognostic factors influencing these outcomes. A retrospective analysis was conducted on 208 osteosarcoma patients treated between January 2013 and December 2018. Patients were divided into two groups: standard chemotherapy group (SC, n = 104) and cisplatin + paclitaxel + high-dose methotrexate (CPM, n = 104). The primary endpoints were progression-free survival (PFS) and overall survival (OS), while secondary endpoints included efficacy assessments. Kaplan-Meier survival curves were used to assess survival distributions, and statistical analyses were performed using SPSS 29.0. The CPM group demonstrated significantly longer PFS (16.85 ± 3.40 months vs. 15.72 ± 3.21 months, <i>P</i> = 0.015) and higher 5-year OS rates (54.81% vs. 40.38%, <i>P</i> = 0.037) compared to the SC group. Completion of chemotherapy and a response rate greater than 90% were identified as strong positive prognostic indicators. In contrast, pathologic fractures at diagnosis, lung metastases, and elevated lactate dehydrogenase levels were associated with poorer outcomes. Multivariate analysis underscored chemotherapy response and treatment adherence as independent survival predictors. The combination of cisplatin and paclitaxel with high-dose methotrexate significantly improves PFS and OS compared to standard chemotherapy. Moreover, treatment completion and achieving a chemotherapy response greater than 90% are critical factors for favorable prognosis.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2618-2630"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of YES1 kinase in regulating cisplatin resistance through iTRAQ-based quantitative proteomic analysis in urothelial carcinoma.","authors":"Chia-Che Wu, Chung-Wen Kuo, Ming-Chun Kuo, Chang-Ting Lin, Ling-Yi Xiao, Li-Chung Chang, Yi-Hua Chen, Shih-Yu Huang, Harvey Yu-Li Su","doi":"10.62347/HBJQ5692","DOIUrl":"10.62347/HBJQ5692","url":null,"abstract":"<p><p>Urothelial carcinoma (UC) is a highly metastatic cancer that frequently develops resistance to platinum-based chemotherapy, although the underlying mechanisms remain unclear. While certain genes have been implicated in UC drug resistance, their specific roles require further validation. In this study, we established a cisplatin-resistant UC cell line (BFTC909 Cis-R) and used iTRAQ analysis to compare differences in protein expression between BFTC909 Cis-R cells and their parental BFTC909 counterparts. iTRAQ mass analysis revealed decreased expression of the tyrosine kinase YES1 in BFTC909 Cis-R cells, along with reduced levels of YES1 and YAP in both BFTC909 Cis-R and T24 Cis-R cells. Moreover, we found that bladder cancer patients with higher YES1 expression had significantly better survival outcomes in our in-house cohort and two public datasets (GSE13507 and GSE169455). Treatment with dasatinib, a YES1 inhibitor, reduced cisplatin-induced cytotoxicity in UMUC-14 cells, suggesting that YES1 influences cisplatin efficacy in UC cells. Our findings indicate that YES1 plays a critical role in cisplatin resistance and may represent a promising therapeutic target in bladder cancer.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2535-2550"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction of abscopal effect combining H101 oncolytic virotherapy with tislelizumab in a patient with advanced hepatocellular carcinoma: a case report.","authors":"Danzhen Ou, Yijing Li, Jingjing Wu, Shunjie Ou, Fangwei Xie","doi":"10.62347/VSQY6496","DOIUrl":"10.62347/VSQY6496","url":null,"abstract":"<p><p>We reported a case of advanced hepatocellular carcinoma (HCC) in a patient who relapsed after first-line chemoimmunotherapy. Remarkably, the combination of H101 oncolytic virotherapy and tislelizumab successfully induced an abscopal effect. Following this treatment, the patient achieved a 24-month survival period, accompanied by complete regression of distant metastatic lesions. Distinct tumor responses were observed at different sites following H101 injection. Lesions showing regression demonstrated higher infiltration of CD3⁺ T cells, CD4⁺ T cells, and eosinophils, along with lower infiltration of neutrophils. Rapid tumor shrinkage was associated with severe local inflammation and a reduction in peripheral white blood cell counts. These findings suggest that oncolytic virotherapy may elicit an abscopal effect by activating and recruiting immune cells into the tumor microenvironment.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2650-2656"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation and predictive modeling of serum exosomal miRNAs and serological biomarkers for lymph node metastasis in gastric cancer.","authors":"Quandong Li, Fang Nie, Dezhi Huang, Yongping Lin, Junjie Wan","doi":"10.62347/AOJE4206","DOIUrl":"10.62347/AOJE4206","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the predictive potential of serum exosomal microRNAs (miRNAs) and traditional serological biomarkers for lymph node metastasis in gastric cancer and to assess their applicability in clinical practice.</p><p><strong>Methods: </strong>This retrospective study included 845 gastric cancer patients treated between January 2020 and December 2023, as the training cohort. Patients were stratified into lymph node-positive (n = 231) and lymph node-negative (n = 614) groups based on postoperative pathological evaluation. Serum exosomal miRNAs and conventional serological biomarkers were quantified and compared between groups. Multivariate logistic regression analysis was conducted to identify independent predictors. Model performance was validated using an independent test cohort comprising 277 patients (74 lymph node-positive, 203 lymph node-negative).</p><p><strong>Results: </strong>Patients with lymph node metastasis exhibited significantly elevated expression of miR-21, miR-20a, miR-27a, and miR-106a. Serological markers that were significantly higher in the lymph node positive group included carbohydrate antigen 724, carcinoembryonic antigen, hepatocyte growth factor, vascular endothelial growth factor, interleukin-6, and circulating cell-free DNA (all P < 0.05). A combined predictive model integrating both miRNA and serological data demonstrated strong diagnostic performance, with an area under the curve of 0.816 in the training cohort and 0.817 in the validation cohort.</p><p><strong>Conclusion: </strong>Serum exosomal miRNAs and serological biomarkers are significantly associated with lymph node metastasis in gastric cancer.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 6","pages":"2579-2594"},"PeriodicalIF":3.6,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}